View ValuationAimed Bio 향후 성장Future 기준 점검 0/6현재 Aimed Bio 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.핵심 정보n/a이익 성장률n/aEPS 성장률Biotechs 이익 성장21.0%매출 성장률n/a향후 자기자본이익률n/a애널리스트 커버리지None마지막 업데이트18 Jun 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesBuy Or Sell Opportunity • Jun 16Now 21% overvaluedOver the last 90 days, the stock has fallen 53% to ₩28,600. The fair value is estimated to be ₩23,679, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 76% per annum over the same time period.분석 기사 • May 25Investors Shouldn't Be Too Comfortable With Aimed Bio's (KOSDAQ:0009K0) EarningsInvestors were disappointed with Aimed Bio Inc.'s ( KOSDAQ:0009K0 ) earnings, despite the strong profit numbers. We did...New Risk • May 24New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 33% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Large one-off items impacting financial results.Buy Or Sell Opportunity • May 20Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to ₩33,300. The fair value is estimated to be ₩41,769, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 75% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 70% per annum over the same time period.Buy Or Sell Opportunity • Apr 24Now 26% overvaluedOver the last 90 days, the stock has fallen 5.5% to ₩50,200. The fair value is estimated to be ₩39,924, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 75% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 70% per annum over the same time period.Buy Or Sell Opportunity • Apr 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to ₩45,300. The fair value is estimated to be ₩57,241, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 79% over the last 3 years. Earnings per share has declined by 30%.공고 • Mar 13Aimed Bio Inc., Annual General Meeting, Mar 27, 2026Aimed Bio Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 9, jeongui-ro 8-gil, songpa-gu, seoul South KoreaBuy Or Sell Opportunity • Mar 04Now 31% undervaluedOver the last 90 days, the stock has risen 17% to ₩51,300. The fair value is estimated to be ₩73,923, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has declined by 57%.Buy Or Sell Opportunity • Jan 28Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at ₩57,200. The fair value is estimated to be ₩73,034, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has declined by 57%.Board Change • Dec 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Inside Director Nam-Gu Her was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측KOSDAQ:A0009K0 - 애널리스트 향후 추정치 및 과거 재무 데이터 (KRW Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/202654,1954,07412,33713,136N/A12/31/202547,2785,02317,49817,860N/A9/30/202520,706-22,751-1,121616N/A6/30/202520,705-19,982-6911,029N/A3/31/202513,221-354-7,034-5,388N/A12/31/202411,760-3,304-6,554-4,874N/A12/31/2023171-9,023-3,440-2,644N/A12/31/2022111-6,168-4,430-3,908N/A애널리스트 향후 성장 전망수입 대 저축률: A0009K0 의 예상 수익 증가율이 절약률(3.1%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: A0009K0 의 수익이 KR 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: A0009K0 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: A0009K0 의 수익이 KR 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 매출: A0009K0 의 수익이 연간 20%보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: A0009K0의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/28 08:20종가2026/07/28 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aimed Bio Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Keunhee SeoSamsung Securities Co. Ltd.
Buy Or Sell Opportunity • Jun 16Now 21% overvaluedOver the last 90 days, the stock has fallen 53% to ₩28,600. The fair value is estimated to be ₩23,679, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 76% per annum over the same time period.
분석 기사 • May 25Investors Shouldn't Be Too Comfortable With Aimed Bio's (KOSDAQ:0009K0) EarningsInvestors were disappointed with Aimed Bio Inc.'s ( KOSDAQ:0009K0 ) earnings, despite the strong profit numbers. We did...
New Risk • May 24New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 33% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Large one-off items impacting financial results.
Buy Or Sell Opportunity • May 20Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to ₩33,300. The fair value is estimated to be ₩41,769, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 75% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 70% per annum over the same time period.
Buy Or Sell Opportunity • Apr 24Now 26% overvaluedOver the last 90 days, the stock has fallen 5.5% to ₩50,200. The fair value is estimated to be ₩39,924, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 75% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 70% per annum over the same time period.
Buy Or Sell Opportunity • Apr 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to ₩45,300. The fair value is estimated to be ₩57,241, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 79% over the last 3 years. Earnings per share has declined by 30%.
공고 • Mar 13Aimed Bio Inc., Annual General Meeting, Mar 27, 2026Aimed Bio Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 9, jeongui-ro 8-gil, songpa-gu, seoul South Korea
Buy Or Sell Opportunity • Mar 04Now 31% undervaluedOver the last 90 days, the stock has risen 17% to ₩51,300. The fair value is estimated to be ₩73,923, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has declined by 57%.
Buy Or Sell Opportunity • Jan 28Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at ₩57,200. The fair value is estimated to be ₩73,034, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has declined by 57%.
Board Change • Dec 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Inside Director Nam-Gu Her was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.